Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V

Status
Status: Commission completed
Project no.
A22-70
Last updated

Report documents

  1. Extract of dossier assessment

    Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V

    published on
    Document type
    PDF document, 814 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 814 kB, EN, not accessible)

  2. Dossier assessment

    Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    Download file : Dossier assessment (PDF document, 2 MB, DE, not accessible)

Dossier assessment

Indication:

Adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 with a CPS ≥ 1

Result of dossier assessment:
  • First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is a suitable therapy of physician’s choice: hint of major added benefit
  • First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is no suitable therapy of physician’s choice: added benefit not proven
  • Patients after first-line chemotherapy and for whom further antineoplastic therapy is an option: added benefit not proven

Press releases

Advanced cervical cancer: Pembrolizumab prolongs life

There is a hint of major added benefit compared with chemotherapy with cisplatin or carboplatin, each plus paclitaxel with or without bevacizumab. These are the main first-line therapies for advanced cervical cancer.
Press release

Additional information

Federal Joint Committee (G-BA)

2023-02-02 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A22-70
Commission
Commission awarded on 19.07.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Pembrolizumab (melanoma, adjuvant) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-72
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Pembrolizumab (melanoma, advanced) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-73
    Last updated

    Status: Commission completed

  3. Addendum

    Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) – Addendum to Commission A21-145

    Project no.
    A22-36
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-35
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A21-34
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Pembrolizumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-163
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-145
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Pembrolizumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-144
    Last updated

    Status: Commission completed

  9. Dossier assessment

    Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-99
    Last updated

    Status: Commission completed

  10. Dossier assessment

    Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-31
    Last updated

    Status: Commission completed

  11. Dossier assessment

    Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-30
    Last updated

    Status: Commission completed

  12. Dossier assessment

    Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-29
    Last updated

    Status: Commission completed

  13. Dossier assessment

    Pembrolizumab (head and neck squamous cell carcinoma, combination therapy) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-101
    Last updated

    Status: Commission completed

  14. Dossier assessment

    Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-100
    Last updated

    Status: Commission completed

  15. Dossier assessment

    Pembrolizumab (urothelial carcinoma, first line) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    Project no.
    A18-89
    Last updated

    Status: Commission completed

  16. Dossier assessment

    Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-67
    Last updated

    Status: Commission completed

  17. Dossier assessment

    Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-46
    Last updated

    Status: Commission completed

  18. Dossier assessment

    Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-23
    Last updated

    Status: Commission completed

  19. Dossier assessment

    Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-06
    Last updated

    Status: Commission completed

  20. Dossier assessment

    Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-55
    Last updated

    Status: Commission completed

  21. Dossier assessment

    Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    Project no.
    A15-33
    Last updated

    Status: Commission completed

  22. Dossier assessment

    Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-71
    Last updated

    Status: Commission completed

  23. Dossier assessment

    Pembrolizumab (bile cancer) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-79
    Last updated

    Status: Commission completed

  24. Dossier assessment

    Pembrolizumab (small bowel cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-78
    Last updated

    Status: Commission completed

  25. Dossier assessment

    Pembrolizumab (gastric cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-77
    Last updated

    Status: Commission completed

  26. Dossier assessment

    Pembrolizumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-76
    Last updated

    Status: Commission completed

  27. Dossier assessment

    Pembrolizumab (colorectal cancer) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-75
    Last updated

    Status: Commission completed

  28. Addendum

    Pembrolizumab (cervical cancer) – Addendum to Commission A22-70

    Project no.
    A22-135
    Last updated

    Status: Commission completed

  29. Dossier assessment

    Pembrolizumab (head and neck squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-148
    Last updated

    Status: Commission completed

  30. Dossier assessment

    Pembrolizumab (endometrial carcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-111
    Last updated

    Status: Commission completed

  31. Dossier assessment

    Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-110
    Last updated

    Status: Commission completed

  32. Dossier assessment

    Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A24-104
    Last updated

    Status: Commission completed

  33. Dossier assessment

    Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-99
    Last updated

    Status: Commission completed

  34. Dossier assessment

    Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V

    Project no.
    A24-46
    Last updated

    Status: Commission completed

  35. Dossier assessment

    Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-03
    Last updated

    Status: Commission completed

  36. Dossier assessment

    Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V

    Project no.
    A24-47
    Last updated

    Status: Commission completed

  37. Dossier assessment

    Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-02
    Last updated

    Status: Commission completed

  38. Dossier assessment

    Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-01
    Last updated

    Status: Commission completed

  39. Dossier assessment

    Pembrolizumab (pleural mesothelioma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-53
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page